The therapeutic potential of CX3CL1 in Alzheimer’s disease is more complex; however, knockout of CX3CR1 appears to be detrimental in mouse models of tauopathy, but beneficial in amyloid expressing mice [21–24]. This evidence concerns the gene CX3CR1 and early-onset autosomal dominant Alzheimer disease.